pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in fibromyalgia

Phase 2

Completed

• Conditions: fibromyalgia; 10018073; 10028302; 10029317

• Registration Number: NL-OMON32088
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

fibromyalgia patients

Exclusion Criteria

Obesity (BMI > 30);
Presence of psychiatric disease;
History of chronic alcohol or drug use;
Known allergy to study medications;
Possibility of pregnancy; and
Lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>painscores on a visual analogue scale (VAS)<br /><br>quality of life: fibromyalgia impact questionnaire (FIQ)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Furthermore this study investigate the pharmacokinetics and pharmacodynamics of<br /><br>(S+)-ketamine in subanaesthetic doses in fybromyalgia.</p><br>